Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Med Res Opin. 2012 Nov;28(11):1831-9. doi: 10.1185/03007995.2012.741577. Epub 2012 Nov 5.

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.

Author information

1
Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA. lei.chen@novartis.com

Abstract

OBJECTIVES:

Monitoring treatment response is an integral part of chronic myeloid leukemia (CML) treatment. The guidelines recommend regular monitoring using standard methods (e.g., real-time quantitative polymerase chain reaction based on the international scale for molecular response) and treatment adjustment when failure is detected among patients treated with imatinib. The objective of this study was to assess the real-world monitoring and therapy adjustment in this patient population in the US.

METHODS:

Twenty-nine physicians from community practices across the US participated in an online chart review. Adult patients with chronic phase CML who initiated imatinib as first-line therapy during 2006-2010 were selected. Information was collected up to 36 months after imatinib initiation, including response monitoring, response status, and therapy adjustment upon treatment failure.

RESULTS:

The study included 297 eligible patients. By 18 months, 47% of patients had received cytogenetic response assessment continuously as recommended by the guidelines. The corresponding proportion was 39% for continuous molecular response assessment. Among patients who experienced treatment failure by 18 months, only 14%-38% of patients switched to a second-generation tyrosine kinase inhibitor as recommended by the National Comprehensive Cancer Network and the European Leukemia Net guidelines.

LIMITATIONS:

Major limitations included limited generalizability and the inability to accurately assess molecular response due to the variations in testing methods during the study period.

CONCLUSIONS:

Based on the guidelines, the rates of treatment monitoring and switching upon failure were low, demonstrating the need for improvement in CML care in community settings in the US.

PMID:
23127201
DOI:
10.1185/03007995.2012.741577
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center